Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle

5 Jun 2018

Abstract excerpt

A primary pathological defect in the heritable eye disorder Stargardt disease is excessive accumulation of cytotoxic lipofuscin bisretinoids in the retina. Age-dependent accumulation of lipofuscin in the retinal pigment epithelium (RPE) matches the age-dependent increase in the incidence of the atrophic (dry) form of age-related macular degeneration (AMD) and therefore may be one of several pathogenic factors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circadian rhythm and melatonin
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29871924
DOI: 10.1074/jbc.ra118.002062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cyclePMID 29871924Read ↗

Complement System Dysregulation and Inflammation in the Retinal Pigment Epithelium of a Mouse Model for Stargardt Macular DegenerationSemantic proximity Read ↗

Evidence of complement dysregulation in outer retina of Stargardt disease donor eyesSemantic proximity Read ↗

Distinct mouse models of Stargardt disease display differences in pharmacological targeting of ceramides and inflammatory responsesSemantic proximity Read ↗

Therapeutic targeting of the complement system in age‐related macular degeneration: a reviewSemantic proximity Read ↗

Severe ocular phenotypes in Rbp4-deficient mice in the C57BL/6 genetic background.Semantic proximity Read ↗

Loss of Complement Factor D suppresses alternative pathway activation but fails to reduce lipofuscin accumulation in the retinal pigmented epithelium of <i> Abca4 <sup>-/-</sup> </i> miceSemantic proximity Read ↗

Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization.Semantic proximity Read ↗

Therapeutic targeting of the complement system in ocular diseaseSemantic proximity Read ↗

Stargardt macular dystrophy and evolving therapiesSemantic proximity Read ↗

Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence.Semantic proximity Read ↗

Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMDSemantic proximity Read ↗

Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.